Program
- Welcome Reception
- Day 1 - Thursday, October 17
- Day 2 - Friday, October 18
- Day 3 - Saturday, October 19
- Download Program and Abstracts
Wednesday, October 16, 2024
16:00 - 18:00 Early Registration
18:00 - 20:00 Welcome Reception
Conference Facilities at the Prague Marriott
Thursday, October 17, 2024
[7:45-8:00] Welcome to IWWM-12
Christian Buske, Jeffrey Matous, and Steven Treon [Workshop Organizers]
[8:00-9:00] Session I
WM Predisposition
Romanos Sklavenitis-Pistofidis, Merav Leiba [Chairs]
Findings from the iSTOP Study
Sigurdur Kristinsson, Landspitali-The National University Hospital of Iceland, Iceland
Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in WM Compared to IgM-MGUS
Stephen Ansell, Mayo Clinic, USA
Multi-Omics for Deciphering Mechanisms of Progression in Pre-Malignant IgM Gammopathies
Simone Ferrero, Università di Torino/Ematologia Universitaria, Italy
Clonal Hematopoiesis in Patients with WM
Adam Sperling, Dana Farber Cancer Institute, USA
[8:45] Panel Discussion, All Session I Speakers
[9:00-10:00] Session II
WM/LPL Genomics I
Bruno Paiva, Christopher Oakes [Chairs]
Using Mutographs to Define the Molecular Landscape and Cell of Origin of WM
Gareth Morgan, N.Y.U. Grossman School of Medicine, USA
Molecular Clusters and Tumor-immune Drivers of IgM Monoclonal Gammopathies
Patrizia Mondello, Mayo Clinic, USA
Clonal architecture and evolutionary history of WM at the single-cell level
Cristina Jiménez, Hospital Universitario de Salamanca, Spain
Chromatin Accessibility Landscape and Regulatory Networks of IgM monoclonal Gammopathies
David Moreno, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain
[9:45] Panel Discussion, All Session II Speakers
[10:00-10:30] Morning Break
[10:30-11:30] Session III
WM/LPL Genomics II
Nikhil Munshi, Marzia Varettoni [Chairs]
Harnessing Epigenetic Signatures for Classification of WM
Christopher Oakes, Ohio State University, James Comprehensive Cancer Center, USA
Landscape of IgH gene repertoire and clinical relevance to LPL/WM
Mu Hao, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital, China
Single Cell multi-omics for minimally invasive assessment of Treatment efficacy in WM
Bruno Paiva, Clinica Universidad de Navarra, Spain
TP53 Alterations in the Management of Waldenstrom’s Macroglobulinemia
Steven Treon, Dana Farber Cancer Institute, USA
[11:15] Panel Discussion, All Session III Speakers
[11:30-12:30] Session IV
Single Cell RNA Analysis
Irene Ghobrial/Bruno Paiva [Chairs]
Single-Cell RNA Analysis of Tumor and Immune Cells in Asymptomatic WM
Romanos Sklavenitis-Pistofidis, Harvard Medical School, Broad Institute of MIT & Harvard , USA
Single-Cell RNA Analysis of MYD88 MUT and WT WM
Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece
Single-Cell RNA reveals Stem Cell like subsets in WM Progression
Xinxin Cao, Peking Union Medical College Hospital, China
Single-Cell RNA reveals Tumor Heterogeneity and Immunosuppressive Microenvironment in WM
Hao Sun, Dana Farber Cancer Institute, USA
[12:15] Panel Discussion, All Session IV Speakers
[12:30-13:30] LUNCH
[13:30-14:00] Session V
Keynote Lectures
Sub-typing WM by Multi-Omic Analysis
Keynote Moderator: Christian Buske
Keynote Speaker: Zachary Hunter, Dana Farber Cancer Institute, USA
BM Stromal Cells and Transcriptional Regulation: Lessons for WM
Keynote Moderator: Christian Buske
Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA
[14:00-15:00] Session VI
Molecular Diagnostics in WM
Ramón García Sanz/Roman Hajek [Chairs]
Clinical Implications of Genomic Profiling
Carlos Fernandez de Larrea Rodríguez, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain
Digital Droplet (ddPCR) for Detection of MYD88 L265P Variants
Daniela Drandi, Università di Torino/Ematologia Universitaria, Italy
Molecular Remissions is an Independent Predictor of Progression-Free Survival in WM
Marzia Varettoni, Fondazione IRCCS Policlinico San Matteo, Italy
Digital Droplet (ddPCR) for Detection of CXCR4 Nonsense Variants
Nickolas Tsakmaklis, Dana Farber Cancer Institute, USA
[14:45] Panel Discussion, All Session VI Speakers
[15:00-15:30] Afternoon Break
[15:30-16:30] Session: VII
MYD88 and BTK Signaling Networks
Ken Anderson/Adrian Wiestner [Chairs]
MYD88 Signaling Cascades
Steven Treon, Dana Farber Cancer Institute, USA
MYD88 L265P Genocopies Activation by Phosphorylation at the TOLL/IL1 receptor (TIR) Domain
Steven Pals, University of Amsterdam, The Netherlands
IRAK Signaling Pathways Demonstrate Divergent Kinase and Scaffold Function
Xia Liu, Dana Farber Cancer Institute, USA
Aberrant Expression of Spliced WNK2 Is an Early event in MYD88-Mutated WM that Activates ERK 1/2
and supports Tumor Growth
Maria Luisa Guerrera, Dana Farber Cancer Institute, USA
[16:15] Panel Discussion, All Session VII Speakers
[17:00-18:00] Session: VIII
Plenary Session I
Gareth Morgan, Zachary Hunter [Chairs]
PLEN 1
TBD
PLEN 2
TBD
PLEN 3
TBD
PLEN 4
TBD
[17:45] Panel Discussion, All Session VIII Speakers
[19:00] Dinner Reception
- Keynote Speaker: TBD
- Presentation of Jan Gosta Waldenstrom Awards
- Presentation of Robert A. Kyle Awards
Friday, October 18, 2024
[8:00-9:00] Session IX
Tumor Immune Microenvironment
Stephen Ansell/ José Martínez Climent [Chairs]
Dysfunctions of Innate and Adaptive Immune Tumor Microenvironment in WM
Jana Jakubikova, Cancer Research Institute, Biomedical Research Center SAS, Slovakia
Deciphering the Immune Microenvironment in WM
Aldo Roccaro, ASST Spedali Civili di Brescia, Italy
Analysis of Molecular and Microenvironment Landscape and Its Role in Drug Resistance in WM
Damien Roos-Weil, Sorbonne University, Groupe hospitalier Pitié-Salpêtrière, France
The Characterization and Modeling of MYD88 L265P mutation and Chromosome 6q Deletion in Murine B-Cells
Ruben Carrasco, Dana Farber Cancer Institute, USA
[8:45] Panel Discussion, All Session IX Speakers
[9:00-10:00] Session X
Chemoimmunotherapy in WM I
Shirley D'Sa/M.J. Kersten [Chairs]
Dexamethasone, rituximab, and cyclophosphamide (DRC) versus Bortezomib-DRC (B-DRC) in WM
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
Long-term Outcomes of FILO Study: Frontline Benda-Rituximab in WM
Veronique Leblond, Hôpital Pitié Salpêtrière,France
Multicenter Observational Study of Benda-Rituximab vs. RCD
Francesco Autore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy
Long-term Outcomes of 678 patients with symptomatic WM
Elham Askari, Hospital Universitario Fundación Jiménez Díaz, Spain
[9:45] Panel Discussion, All Session X Speakers
[10:00-10:30] Morning Break
[10:30-11:30] Session XI
Chemoimmunotherapy in WM II
Veronique Leblond/Meletios Dimopoulos [Chairs]
Role of Proteasome Inhibitors in WM
M.J. Kersten, University of Amsterdam, The Netherlands
Management of Transformed WM
Eric Durot, Hopital Robert Debre, Hematologie Clinique, France
Final Analysis of Innovative Study; Ibrutinib Rituximab vs. Placebo/Rituximab: Clinical and Genomic Findings
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
Comparative Outcomes of Benda-R vs. Ibrutinib in Frontline WM
Jithma Abeykoon, Mayo Clinic, USA
[11:15] Panel Discussion, All Session XI Speakers
[11:30-12:30] Session XII
BTK-Inhibitors in WM I
Stathis Kastritis/ Marek Trneny [Chairs]
Long Term Findings of ASPEN Study: Clinical Outcomes
Meletios Dimopoulos, University of Athens School of Medicine, Greece
Long Term Updates on Ibrutinib and Venetoclax in Frontline WM
Jorge Castillo, Dana Farber Cancer Institute, USA
ECWM-2 Prospective Study
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
BRAWM Study: Bendamustine, Rituximab and Acalabrutinib in Frontline WM
Neil Berinstein, Odette Cancer Center, Canada
[12:15] Panel Discussion, All Session XII Speakers
[12:30-13:30] LUNCH
[13:30-14:30] Session: XIII
BTK-Inhibitors in WM II
Alessandra Tedeschi/ Ranjana Advani [Chairs]
Pirtobrutinib in relapsed/refractory WM: Results from Bruin Study
- Lia Palomba, Memorial Sloan-Kettering Cancer Center, USA
Tirabrutinib in Symptomatic WM and Bing-Neel Syndrome (BNS)
Naohiro Sekiguchi, National Hospital Organization Disaster Medical Center ,Japan
Orelabrutinib in Relapsed/Refractory WM: Long-Term Follow-up
Xinxin Cao, University of Jinan, School of Biological Science & Technology, China
Prospective Study of Acalabrutinib and Rituximab in Symptomatic Anti-MAG mediated IgM peripheral neuropathy
Shayna Sarosiek, Dana Farber Cancer Institute, USA
[14:15] Panel Discussion, All Session XIII Speakers
[14:30-15:30] Session: XIV
BTK-I Intolerant and Resistant Disease
Carlos Fernández de Larrea Rodríguez, Prashant Kapoor [Chairs]
Dose reduction following ibrutinib intolerance in WM patients
Shayna Sarosiek, Dana Farber Cancer Institute, USA
Zanubrutinib for patient’s intolerant of prior BTK-I
Mazyar Shadman, Fred Hutchinson Cancer Research Center, USA
Bortezomib for Patients Failing BTK-I
Jahanzaib Khwaja, University College London Hospitals, UK
BGB-16673 BTK Degrader
John Seymour, Peter MacCallum Cancer Centre, Australia
[15:15] Panel Discussion, All Session XIV Speakers
[15:30-16:30] Session XV
Keynote Lectures
Genomic Evolution and Resistance Following BTK-Inhibitors in CLL:
Lessons for Sequencing and Managing BTK-Inhibitors
Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, USA
Keynote Speaker: Jennifer Brown, Dana Farber Cancer Institute, USA
Role of BTK Inhibitors as Facilitators of Cellular Immunotherapies
Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, USA
Keynote Speaker: Adrian Wiestner, NHLBI, NIH, Hematology Branch, USA
[16:30-17:00] Session XVI
IWWM12 Poster Highlights
Andrew Branagan, Josephine Vos [Chairs]
[17:00-18:30] Poster Session
[19:00] Faculty Dinner Reception
Saturday, October 19, 2024
[8:00-9:00] Session XVII
Special Topics Lectures
Moshe Gatt, Claudio Cerchione [Chairs]
Management of IgM De-myelinating neuropathy
Speaker: Shirley D’Sa, UC London Hospitals NHS, UK
Management of Bing Neel Syndrome
Speaker: Monique Minnema, University of Utrecht, The Netherlands
Diagnostic Workup and management of WM-related Amyloid
Speaker: Giampaolo Merlini, University of Pavia, Italy
Diagnostic Workup and Management of Monoclonal IgM-related Cold Agglutinin Disease
Speaker: Josephine Vos, University of Amsterdam, The Netherlands
[8:45] Panel Discussion, All Session XVII Speakers
[9:00-10:00] Session: XVIII
Plenary Session II
Ranjana Advani, Meletios Dimopoulos [Chairs]
PLEN 5
TBD
PLEN 6
TBD
PLEN 7
TBD
PLEN 8
TBD
[9:45] Panel Discussion, All Session XVIII Speakers
[10:00-10:30] Morning Break
[10:30-12:30] Session XIX
Great Debates in WM
Eva Kimby, Irene Ghobrial [Chairs]
[10:30-11:00] Great Debate I
What should be the standard Frontline Treatment for WM: Benda-R?
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. of Internal Medicine III, Germany
What should be the standard Frontline Treatment for WM: CDR?
Stathis Kastritis, National and Kapodistrian University of Athens, Greece
What should be the standard Frontline Treatment for WM: BTK-I?
Alessandra Tedeschi, A. O. Ospedale Niguarda Ca' Granda, Italy
[11:00-11:30] Great Debate II
Definitive Duration Combination Therapy with BTK-I
Neil Berinstein, Odette Cancer Center, Canada
Single-Agent Indefinite Duration BTK-I
Prashant Kapoor, Mayo Clinic, USA
[11:30-12:00] Great Debate III
Patients with Acquired Covalent BTK-Inhibitor Resistance: Pirtobrutinib?
- Lia Palomba, Memorial Sloan Kettering Cancer Center, USA
Patients with Acquired Covalent BTK-Inhibitor Resistance: Venetoclax?
Jorge Castillo, Dana Farber Cancer Institute, USA
[12:00-12:30] Great Debate IV
Should TP53 Alterations be Factored into Treatment Decision making -yes?
Ramon Garcia Sanz, University Hospital Gregorio Marañón, Spain
Should TP53 Alterations be Factored into Treatment Decision making -no?
Shirley D’Sa, University College London Hospitals NHS Trust, UK
[12:30-13:30] LUNCH
[13:30-14:30] Session XX
Novel Drug Development for WM
Ramon Garcia Sanz, Lugui Qiu [Chairs]
Development of Highly potent and selective biovailable Protacs (proteolysis-targeting chimeras) targeting HCK
John Hatcher, Dana Farber Cancer Institute, USA
Development of IRAK1/IRAK4 Bifunctional Protacs (proteolysis-targeting chimeras) for MYD88 mutated WM
Sara Buhrlage, Dana Farber Cancer Institute, USA
Pacritinib is a Highly Potent Inhibitor of HCK and IRAK and Triggers High Levels of Apoptosis in WM
Shirong Liu, Dana Farber Cancer Institute, USA
Pre-clinical Models for Prediction of Immunotherapy Outcomes and Immune Evasion
Jose Martínez Climent, University of Navarra, Spain
[14:15] Panel Discussion, All Session XX Speakers
[14:30-15:30] Session XXI
Clinical Trials in Progress for WM I
Efstathios Kastritis / Prashant Kapoor [Chairs]
Carfilzomib With and Without Ibrutinib in Frontline and Relapsed/Refractory WM (CZAR-1)
Meletios Dimopoulos, University of Athens School of Medicine, Greece
Rainbow Trial: Ibrutinib Rituximab vs. DRC in Newly diagnosed WM
Rebecca Auer, Barts Health NHS Trust, UK
Zanubrutinib plus Benda-R in Newly diagnosed WM
Shuhua Yi, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), China
Pirtobrutinib and Venetoclax in relapsed or refractory WM
Jorge Castillo, Dana Farber Cancer Institute, USA
[15:15] Panel Discussion, All Session XXI Speakers
[15:30-16:00] Afternoon Break
[16:00-17:00] Session XXII
Clinical Trials in Progress for WM II
Evangelos Terpos/ Prashant Kapoor [Chairs]
Loncastuxumab in Relapsed/Refractory WM
Shayna Sarosiek, Dana Farber Cancer Institute, USA
Sonrotoclax for Relapsed/Refractory WM
Jeffrey Matous, Colorado Blood Cancer Institute, USA
Multi-center Trial of Ipofosine in Relapsed/Refractory WM
Andrei Shustov, Cellectar Biosciences, USA
CD20-Directed CAR-T Cell
Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA
[16:45] Panel Discussion, All Session XXII Speakers
[17:00-18:00] Session XXIII
Clinical Trials in Progress for WM III
Roger Owen, Pierre Morel [Chairs]
WM-NET Clinical Trial Priorities
Jorge Castillo, Dana Farber Cancer Institute, USA
ECWM Clinical Trial Priorities
Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany
[19:30] Dinner Reception and Closing Ceremonies
- Keynote Speaker:
- Presentation of Peter S. Bing Humanitarian Awards
- Presentation of Junior Investigator Awards
- Announcement and Welcome to IWWM-13